The First Bethune Hospital of Jilin University
Welcome,         Profile    Billing    Logout  
 0 Trials 
32 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gao, Sujun
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
NCT06312475: Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Recruiting
3
51
RoW
KN057
Suzhou Alphamab Co., Ltd.
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
10/25
12/25
NCT06569108: Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors

Recruiting
3
111
RoW
KN057
Suzhou Alphamab Co., Ltd.
Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor
10/26
12/26
NCT06525519: Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis

Not yet recruiting
3
104
RoW
ATLG
Institute of Hematology & Blood Diseases Hospital, China
Hematopoietic Stem Cell Transplantation
07/25
07/26
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in Japan for 2L+ multiple myeloma (based on DREAMM-8 trial)
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial)
Hourglass Oct 2024 - Dec 2024 : Acceptance of regulatory submission in US for 2L+ multiple myeloma
More
Recruiting
3
357
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
05/29
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Recruiting
3
182
RoW
Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Graft-versus-host Disease
10/29
12/30
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Checkmark Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Hourglass Sep 2021 - Dec 2021 : Submission for r/r DLBCL
Hourglass Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
Active, not recruiting
3
440
Europe, Canada, Japan, US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin
ADC Therapeutics S.A., ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
06/25
06/28
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Recruiting
3
552
RoW
Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA)
TJ Biopharma Co., Ltd.
Myelodysplastic Syndromes(MDS)
03/27
03/27
wAIHA, NCT05535933: HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Recruiting
2/3
110
RoW
HMPL-523(300mg PO QD), Sovleplenib, Placebo
Hutchison Medipharma Limited
Warm Antibody Autoimmune Hemolytic Anemia
09/26
11/26
NCT06511895: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)

Recruiting
2
150
RoW
AZD4205
Dizal Pharmaceuticals
Peripheral T Cell Lymphoma
05/25
12/26
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Enrolling by invitation
2
64
RoW
ABSK021
Abbisko Therapeutics Co, Ltd
cGvHD
10/26
12/26
SEARCH, NCT03992339: A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hourglass Jul 2024 - Dec 2024 : Approval for R/R DLBCL in Thailand, Malaysia and Indonesia
Hourglass Jan 2023 - Dec 2023 : Market entry for endometrial cancer
Completed
2
60
RoW
ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle, Selinexor
Antengene Corporation
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
05/23
12/23
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma

Active, not recruiting
2
62
RoW
Rocbrutinib, NWP-775, LP-168
Guangzhou Lupeng Pharmaceutical Company LTD.
Mantle Cell Lymphoma (MCL)
12/24
12/25
STSP-0601-04, NCT06289166: Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Recruiting
2
25
RoW
STSP-0601 for Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hemophilia
02/25
02/25
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Recruiting
2
185
RoW
HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor
Hutchison Medipharma Limited
Marginal Zone Lymphoma, Follicular Lymphoma
04/24
12/24
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis
Checkmark First patient dosed as a monotherapy in patients with 2L myelofibrosis
Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis
Active, not recruiting
2
112
Europe, US, RoW
Selinexor, Physician's Choice Treatment
Karyopharm Therapeutics Inc
Myelofibrosis
01/25
01/25
NCT04202003: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Checkmark Efficacy data from trial in combination with azacitidine for MDS
Sep 2022 - Sep 2022: Efficacy data from trial in combination with azacitidine for MDS
Checkmark Data from a study in combination with azacitidine for MDS at ESMO 2022
Sep 2022 - Sep 2022: Data from a study in combination with azacitidine for MDS at ESMO 2022
Completed
1/2
105
RoW
TJ011133
TJ Biopharma Co., Ltd.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS)
12/23
12/23
NCT06580301: Study of YK012 in B-cell Acute Lymphoblastic Leukemia

Recruiting
1/2
46
RoW
YK012, YK012 for Injection
Excyte Biopharma Ltd
B-cell Acute Lymphoblastic Leukemia
12/26
06/27
NCT06122831: A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)

Recruiting
1/2
92
RoW
TQ05105 Tablets, TQB3617 Capsules
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Myelofibrosis
12/26
04/27
TQB2928-Ib-01, NCT06008405: Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy

Recruiting
1
48
RoW
TQB2928 Injection + Azacitidine for injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
05/25
05/25
APG-115-AC101, NCT04275518: A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Recruiting
1
102
RoW
APG-115, Azacitidine, Cytarabine
Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
12/25
12/25
INFINITE, NCT04328662: A Study of Ninlaro in Real World Clinical Practice in China

Active, not recruiting
N/A
482
RoW
Takeda
Multiple Myeloma, Neoplasms, Plasma Cell
09/25
09/25
Zhang, Songling
SKB264-II-06, NCT05642780: SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Recruiting
2
240
Europe, Canada, US, RoW
SKB264, Pembrolizumab, Keytruda
Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc.
Solid Tumor
11/26
12/27
BAT-8006-001-CR, NCT05378737: Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Recruiting
1
216
RoW
BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection
Bio-Thera Solutions
Advanced Solid Tumors
12/24
12/25
Li, Jiajia
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
Tang, Tongyu
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
Li, Nainong
NCT06525519: Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis

Not yet recruiting
3
104
RoW
ATLG
Institute of Hematology & Blood Diseases Hospital, China
Hematopoietic Stem Cell Transplantation
07/25
07/26
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Recruiting
3
182
RoW
Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Graft-versus-host Disease
10/29
12/30
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Enrolling by invitation
2
64
RoW
ABSK021
Abbisko Therapeutics Co, Ltd
cGvHD
10/26
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gao, Sujun
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
NCT06312475: Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Recruiting
3
51
RoW
KN057
Suzhou Alphamab Co., Ltd.
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
10/25
12/25
NCT06569108: Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors

Recruiting
3
111
RoW
KN057
Suzhou Alphamab Co., Ltd.
Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor
10/26
12/26
NCT06525519: Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis

Not yet recruiting
3
104
RoW
ATLG
Institute of Hematology & Blood Diseases Hospital, China
Hematopoietic Stem Cell Transplantation
07/25
07/26
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in Japan for 2L+ multiple myeloma (based on DREAMM-8 trial)
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial)
Hourglass Oct 2024 - Dec 2024 : Acceptance of regulatory submission in US for 2L+ multiple myeloma
More
Recruiting
3
357
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
05/29
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Recruiting
3
182
RoW
Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Graft-versus-host Disease
10/29
12/30
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Checkmark Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Hourglass Sep 2021 - Dec 2021 : Submission for r/r DLBCL
Hourglass Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
Active, not recruiting
3
440
Europe, Canada, Japan, US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin
ADC Therapeutics S.A., ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
06/25
06/28
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Recruiting
3
552
RoW
Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA)
TJ Biopharma Co., Ltd.
Myelodysplastic Syndromes(MDS)
03/27
03/27
wAIHA, NCT05535933: HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Recruiting
2/3
110
RoW
HMPL-523(300mg PO QD), Sovleplenib, Placebo
Hutchison Medipharma Limited
Warm Antibody Autoimmune Hemolytic Anemia
09/26
11/26
NCT06511895: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)

Recruiting
2
150
RoW
AZD4205
Dizal Pharmaceuticals
Peripheral T Cell Lymphoma
05/25
12/26
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Enrolling by invitation
2
64
RoW
ABSK021
Abbisko Therapeutics Co, Ltd
cGvHD
10/26
12/26
SEARCH, NCT03992339: A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hourglass Jul 2024 - Dec 2024 : Approval for R/R DLBCL in Thailand, Malaysia and Indonesia
Hourglass Jan 2023 - Dec 2023 : Market entry for endometrial cancer
Completed
2
60
RoW
ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle, Selinexor
Antengene Corporation
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
05/23
12/23
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma

Active, not recruiting
2
62
RoW
Rocbrutinib, NWP-775, LP-168
Guangzhou Lupeng Pharmaceutical Company LTD.
Mantle Cell Lymphoma (MCL)
12/24
12/25
STSP-0601-04, NCT06289166: Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Recruiting
2
25
RoW
STSP-0601 for Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hemophilia
02/25
02/25
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Recruiting
2
185
RoW
HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor
Hutchison Medipharma Limited
Marginal Zone Lymphoma, Follicular Lymphoma
04/24
12/24
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis
Checkmark First patient dosed as a monotherapy in patients with 2L myelofibrosis
Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis
Active, not recruiting
2
112
Europe, US, RoW
Selinexor, Physician's Choice Treatment
Karyopharm Therapeutics Inc
Myelofibrosis
01/25
01/25
NCT04202003: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Checkmark Efficacy data from trial in combination with azacitidine for MDS
Sep 2022 - Sep 2022: Efficacy data from trial in combination with azacitidine for MDS
Checkmark Data from a study in combination with azacitidine for MDS at ESMO 2022
Sep 2022 - Sep 2022: Data from a study in combination with azacitidine for MDS at ESMO 2022
Completed
1/2
105
RoW
TJ011133
TJ Biopharma Co., Ltd.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS)
12/23
12/23
NCT06580301: Study of YK012 in B-cell Acute Lymphoblastic Leukemia

Recruiting
1/2
46
RoW
YK012, YK012 for Injection
Excyte Biopharma Ltd
B-cell Acute Lymphoblastic Leukemia
12/26
06/27
NCT06122831: A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)

Recruiting
1/2
92
RoW
TQ05105 Tablets, TQB3617 Capsules
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Myelofibrosis
12/26
04/27
TQB2928-Ib-01, NCT06008405: Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy

Recruiting
1
48
RoW
TQB2928 Injection + Azacitidine for injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
05/25
05/25
APG-115-AC101, NCT04275518: A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Recruiting
1
102
RoW
APG-115, Azacitidine, Cytarabine
Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
12/25
12/25
INFINITE, NCT04328662: A Study of Ninlaro in Real World Clinical Practice in China

Active, not recruiting
N/A
482
RoW
Takeda
Multiple Myeloma, Neoplasms, Plasma Cell
09/25
09/25
Zhang, Songling
SKB264-II-06, NCT05642780: SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Recruiting
2
240
Europe, Canada, US, RoW
SKB264, Pembrolizumab, Keytruda
Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc.
Solid Tumor
11/26
12/27
BAT-8006-001-CR, NCT05378737: Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Recruiting
1
216
RoW
BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection
Bio-Thera Solutions
Advanced Solid Tumors
12/24
12/25
Li, Jiajia
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
Tang, Tongyu
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
Li, Nainong
NCT06525519: Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis

Not yet recruiting
3
104
RoW
ATLG
Institute of Hematology & Blood Diseases Hospital, China
Hematopoietic Stem Cell Transplantation
07/25
07/26
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Recruiting
3
182
RoW
Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Graft-versus-host Disease
10/29
12/30
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Enrolling by invitation
2
64
RoW
ABSK021
Abbisko Therapeutics Co, Ltd
cGvHD
10/26
12/26

Download Options